Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: bob oserin who wrote (2461)	2/7/1999 10:23:00 AM
From: AJAG	Read Replies (1) \| Respond to of 4676

Gentlemen- One possibility for the equity offering now is the possibility that ISIP is thinking of negotiating a deal for one of its products in trials with a major pharmaceutical company. I have noticed that biotechs will often decide to raise some cash before negotiating such a deal so that they will be in a position of strength (ie., by having enough cash to take the product to market themselves, they will not look like they are desperate for the deal to happen). Alternatively, maybe ISIP wants to be in a position to pick up some other company's products cheap. See, eg, LGND's acquisition of Ontak for cash (Ontak was approved by the FDA last week). It is obvious that small cap biotechs are running out of cash. Look for more acquisitions of such companies by the Chirons, Genentechs and Amgens, who have lots of cash, or Big Pharma. See, eg, WLA-AGPH.